Detalles de la búsqueda
1.
Etiology-independent activation of the LTß-LTßR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.
Hepatology
; 2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916976
2.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 436, 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38589856
3.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Liver Int
; 43(8): 1803-1812, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37452505
4.
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Int J Cancer
; 151(8): 1310-1320, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35723131
5.
Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma.
Liver Int
; 42(12): 2855-2870, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35983950
6.
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Breast Cancer Res
; 22(1): 33, 2020 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252811
7.
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Pharmacogenomics J
; 19(5): 465-472, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30713338
8.
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 563, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38711003
9.
Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Future Oncol
; 15(26): 3015-3024, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31424273
10.
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Oncologist
; 23(10): 1178-1187, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29739893
11.
Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma.
Lancet Oncol
; 21(12): 1538-1539, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33284112
12.
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
JAMA Netw Open
; 7(1): e2350756, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38190183
13.
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
Clin Cancer Res
; 30(2): 436-443, 2024 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610454
14.
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
Eur J Cancer
; 203: 114043, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38598921
15.
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Target Oncol
; 19(3): 359-370, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38691295
16.
Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma.
Cancer Med
; 12(8): 10156-10168, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36938752
17.
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Clin Cancer Res
; 29(23): 4853-4862, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773629
18.
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Eur J Cancer
; 190: 112945, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441940
19.
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Eur J Cancer
; 195: 113396, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37924647
20.
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Target Oncol
; 18(1): 139-145, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689074